Colorectal cancer: Molecular mutations and polymorphisms

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Sameer, Aga Syed ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Colorectal cancer; Hypermethylation; Medical genetics; Mutations; Polymorphism

Indexed keywords

5, 10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APC PROTEIN; AXIN; BETA CATENIN; K RAS PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER INCIDENCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYP2E1 GENE; DNA POLYMORPHISM; EPIGENETICS; GENE MUTATION; HEREDITARY COLORECTAL CANCER; HUMAN; INCIDENCE; MICROSATELLITE INSTABILITY; NONHUMAN; NQO1 GENE; PROTO ONCOGENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 84881276734     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00114     Document Type: Article

References (98)

1. Arnold, C. N., Goel, A., Niedzwiecki, D., and Dowell, J. M. (2004). APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol. Ther. 3, 960-964.
2. Attisano, L., and Lee-Hoeflich, S. T. (2001). The Smads. Genome Biol. 2, 3010.1-3010.8.
3. Attisano, L., and Wrana, J. L. (2000). Smads as transcriptional co-modulators. Curr. Opin. Cell Biol. 12, 235-243.
4. Bagley, P. J., and Selhub, J. A. (1998). common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. U.S.A. 95, 13217-13220.
5. Baker, S. K., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 244, 217-221.
6. Bazan, V., Migliavacca, M., Zanna, I., Tubiolo, C., Grassi, N., Latteri, M. A., et al. (2002). Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann. Oncol. 13, 1438-1446.
7. Behrens, J. (2005). The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem. Soc. Trans. 33, 672-676.
8. Benatti, P., Gafa, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., et al. (2005). Microsatellite instability and CRC prognosis. Clin. Cancer Res. 11, 8332-8340.
9. Boguski, M., and McCormick, F. (1993). Proteins regulating Ras and its relatives. Nature 366, 643-653.
10. Bojesen, S. E., and Nordestgaard, B. G. (2008). The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 7, 158-163.
11. Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., et al. (1998). National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in CRC. Cancer Res. 58, 5248-5257.
12. Borrensen-Dale, A., Lothe, R. A., Meling, G. I., Hainut, P., Rognum, T. O., and Skovlund, E. (1998). TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin. Cancer Res. 4, 203-210.
13. Brink, M., Weijenberg, M. P., de Goeij, A. F., Roemen, G. M., Lentjes, M. H., de Bruine, A. P., et al. (2005). Meat consumption and K-ras mutations in sporadic colon and rectal cancer in The Netherlands cohort study. Br. J. Cancer 92, 1310-1320.
14. Center, M. M., Jemal, A., Smith, R. A., and Ward, E. (2009). Worldwide variations in colorectal cancer. CA Cancer J. Clin. 59, 366-378.
15. Chao, C., Zhang, Z.-F., Berthiller, J., Boffetta, P., and Hashibe, M. N. A. D. (2006). (P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung. Bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 979-987.
16. Chen, H., Lum, A., Seifried, A., Wilkens, L. R., and Marchand, L. L. (1999). Association of the NAD(P)H:quinone oxidoreductase 609C3T polymorphism with a decreased lung cancer risk1. Cancer Res. 59, 3045-3048.
17. Chen, J., Röcken, C., Lofton-Day, C., Schulz, H. U., Müller, O., Kutzner, N., et al. (2005). Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 26, 37-43.
18. Cicek, M. S., Nock, N. L., Li, L., Conti, D. V., Casey, G., and Witte, J. S. (2004). Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev. 13, 1331-1336.
19. Conlin, A., Smith, G., Carey, F. A., Wolf, C. R., and Steele, R. J. (2005). The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54, 1283-1286.
20. Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle-Teijeiro, J., Medeiros, R., et al. (2008). Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32. doi:10.1186/1471-2407-8-32
21. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
22. Debuire, B., Lemoine, A., and Saffroy, R. (2002). CTNNB1 (catenin, beta-1). Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/CTNNB1ID71.html
23. Dolcetti, R., Viel, A., Doglioni, C., Russo, A., Guidoboni, M., Capozzi, E., et al. (1999). High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. 154, 1805-1813.
24. Domingo, E., and Schwartz, S. Jr. (2004). BRAF. Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/BRAFID828.html
25. Donovan, S., Shannon, K. M., and Bollag, G. (2002). GTPase activating poteins: critical regulators of intracellular signaling. BBA Rev. Cancer 1602, 23-45.
26. Dukes, C. E. (1932). The classification of cancer of the rectum. J. Pathol. Bacteriol. 35, 323.
27. Dumont, P., Leu, J. I., Della Pietra, A. C. III, George, D. L., and Murphy, M. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365.
28. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., et al. (2001). RAS and p16 aberrations confer poor prognosis in human CRC. J. Clin. Oncol. 19, 299-304.
29. Esteller, M., and Herman, J. G. (2002). Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 196, 1-7.
30. Esteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M. A., et al. (2000). Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60, 4366-4371.
31. Fearnhead, N. S., Britton, M. P., and Bodmer, W. F. (2001). The ABC of APC. Hum. Mol. Genet. 10, 721-733.
32. Fearon, E. R. (1994). Molecular genetic studies of the adenoma-carcinoma sequence. Adv. Intern. Med. 39, 123-147.
33. Fearon, E. R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
34. Felley-Bosco, E., Weston, A., Cawley, H. M., Bennett, W. P., and Harris, C. C. (1993). Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am. J. Hum. Genet. 53, 752-759.
35. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10, 111-113.
36. Guengerich, F. P., Kim, D. H., and Iwasaki, M. (1991). Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179.
37. Hamelin, P. (1998). APC (adenomatous polyposis coli). Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/APC118.html
38. Hardy, R. G., Meltzer, S. T., and Jankowski, J. A. (2001). "Molecular basis for risk factors," in ABC of CRC, eds D. J. Kerr, A. N. Young, and F. D. R. Hobbs (London: British Medical Journal Books), 5.
39. Harris, C. C., and Hollstein, M. (1993). Clinical implication of the p53 tumor suppressor gene. N. Engl. J. Med. 329, 1318-1327.
40. Hayashi, S., Watanabe, J., and Kawajiri, K. (1991). Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. 110, 559-565.
41. Hiltunen, M. O., Alhonen, L., Koistinaho, J., Myöhänen, S., Kashiwaba, M., Osakabe, M., et al. (1997). Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int. J. Cancer 70, 644-648.
42. Hong-Tao, X., Qiang, W., Yang, L., Lian-He, Y., Shun-Dong, D., Yang, H., et al. (2007). Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Ann. Surg. Oncol. 14, 3251-3259.
43. Hsieh, J. S., Lin, S. R., Chang, M. Y., Chen, F. M., Lu, C. Y., Huang, T. J., et al. (2005). APC. K-ras, and p53 gene mutations in CRC patients: correlation to clinicopathologic features and postoperative surveillance. Am. Surg. 71, 336-343.
44. Ignaszak-Szczepaniak, M., Horst-Sikorska, W., Sawicka, J., Kaczmarek, M., and Slomski, R. (2006). The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncol. Rep. 16, 65-71.
45. Ionita-Laza, I., Rogers, A. J., Lange, C., Raby, B. A., and Lee, C. (2009). Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. Genomics 93, 22-26.
46. Kang, G. H., Lee, S., Kim, J. S., and Jung, H. Y. (2003). Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab. Invest. 83, 635-641.
47. Kerr, D. J., Young, E. M., and Hobbs, F. D. R. (2001). ABC Of Colorectal Cancer. 1st Edn, London: British Medical Journal
48. Kharasch, E. D., and Thummel, K. E. (1993). Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 79, 795-807.
49. Khosrave-far, R., and Der, C. J. (1994). The ras signal transduction pathway. Cancer Metastasis Rev. 13, 67-89.
50. Kono, S., and Chen, K. (2005). Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci. 96, 535-542.
51. Lammi, L., Arte, S., Somer, M., Jarvinen, H., Lahermo, P., Thesleff, I., et al. (2004). Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am. J. Hum. Genet. 74, 1043-1050.
52. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E., and George, D. L. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6, 443-450.
53. Levine, A. J., Momand, J., and Finlay, C. A. (1991). The p53 tumour suppressor gene. Nature 351, 453-456.
54. Li, X., Dumont, P., Della, P. A., Shetler, C., and Murphy, M. E. (2005). The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 280, 24245-24251.
55. Lind, G. E., Thorstensen, L., Løvig, T., Meling, G. I., Hamelin, R., Rognum, T. O., et al. (2004). A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol. Cancer 3, 28.
56. Ma, J., Stampfer, M. J., Giovannucci, E., Artigas, C., Hunter, D. J., Fuchs, C., et al. (1997). Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 57, 1098-1102.
57. Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25, 47-54.
58. Massagué, J., Blain, S. W., and Lo, R. S. (2000). TGF-β signaling in growth control, cancer and heritable disorders. Cell 103, 295-309.
59. Miller, R. D., Phillips, M. S., Jo, I., Donaldson, M. A., Studebaker, J. F., Addleman, N., et al. (2005). High-density single-nucleotide polymorphism maps of the human genome. Genomics 86, 117-126.
60. Morita, M., Tabata, S., Tajima, O., Yin, G., Abe, H., and Kono, S. (2008). Genetic polymorphisms of CYP2E1 and risk of colorectal adenomas in the self defense forces health study. Cancer Epidemiol. Biomarkers Prev. 17, 1800-1807.
61. Murphy, M. E. (2006). Polymorphic variants in the p53 pathway. Cell Death Differ. 13, 916-920.
62. Nomura, F., Itoga, S., Uchimoto, T., Tomonaga, T., Nezu, M., Shimada, H., et al. (2003). Transcriptional activity of the tandem repeat polymorphism in the 5'-flanking region of the human CYP2E1 gene. Alcohol. Clin. Exp. Res. 27, 42S-46S.
63. O'Brien, M. J., Winawer, S. J., and Zauber, A. G. (2004). Flat adenomas in the national polyp study: is there increased risk for high-grade dysplasia initially or during surveillance? Clin. Gastroenterol. Hepatol. 2, 905-911.
64. Paula, M. C., and Harold, F. (2002). The genetics of CRC. Ann. Intern. Med. 137, 603-612.
65. Pietsch, E. C., Humbey, O., and Murphy, M. E. (2006). Polymorphisms in the p53 pathway. Oncogene 25, 1602-1611.
66. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev. 14, 1837-1851.
67. Remvikos, Y., Laurent-Puig, P., Salmon, R. J., Frelat, G., Dutrillaux, B., and Thomas, G. (1990). Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int. J. Cancer 45, 450-456.
68. Ross, D. (2004). NQO1. Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/NQO1ID375.html
69. Roth, S., Johansson, M., Loukola, A., Peltomaki, P., Jarvinen, H., Mecklin, J.-P., et al. (2003). Mutation analysis of SMAD2, SMAD3, and SMAD4 genes in hereditary non-polyposis CRC. J. Cell. Sci. 11, 413-419.
70. Rowan, A. J., Lamlum, H., Ilyas, M., Wheeler, J., Straub, J., Papadopoulou, A., et al. (2000). APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits." Proc. Natl. Acad. Sci. U.S.A. 97, 3352-3357.
71. Saffroy, R., Lemoine, A., and Debuire, B. (2005). MTHFR (5,10-Methylenetetrahydrofolate reductase). Atlas Genet Cytogenet Oncol Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/MTHFRID41448ch1p36.html
72. Saffroy, R., Lemoine, A., and Debuire, B. (2004). SMAD4 (mothers against decapentaplegic homolog 4 (Drosophila)). Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/SMAD4ID371.html
73. Savas, S., and Liu, G. (2009). Studying genetic variations in cancer prognosis (and risk): a primer for clinicians. Oncologist 14, 657-666.
74. Sayar, N., and Banerjee, S. (2007). Colon: Colorectal adenocarcinoma. Atlas Genet Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Tumors/colon5006.html
75. Schubbert, S., Shannon, K., and Bollag, G. (2007). Hyperactive Ras in developmental disorders and Cancer. Nat. Rev. Cancer 7, 295-308.
76. Schutte, M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., et al. (1996). DPC4 gene in various tumor types. Cancer Res. 56, 2527-2530.
77. Shi, Y. (2001). Structural insights on Smad function in TGF-β signaling. Bioessays 23, 223-232.
78. Siegel, D., Gustafson, D. L., Dehn, D. L., Han, J. Y., Boonchoong, P., Berliner, L. J., et al. (2004). NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 65, 1238-1247.
79. Soussi, T., and Beroud, C. (2001). Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1, 233-240.
80. Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., and Matlashewski, G. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19, 1092-1100.
81. Tirnauer, J. (2005). APC (adenomatous polyposis coli). Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Genes/APC118.html
82. Toyama, T., Zhang, Z., Nishio, M., Hamaguchi, M., Kondo, N., Iwase, H., et al. (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9, R34.
83. Tsuchiya, T., Tamura, G., Sato, K., Endoh, Y., Sakata, K., Jin, Z., et al. (2000). Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 19, 3642-3646.
84. Ulusoy, G., Arinç, E., and Adali, O. (2007). Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population. Arch. Toxicol. 81, 711-718.
85. Vainio, H., and Miller, A. B. (2003). Primary and secondary prevention in CRC. Acta Oncol. 42, 809-815.
86. Virmani, A. K., Rathi, A., Sathyanarayana, U. G., Padar, A., Huang, C. X., Cunnigham, H. T., et al. (2001). Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin. Cancer Res. 7, 1998-2004.
87. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., et al. (1988). Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532.
88. Wagner, C. (1995). "Biochemical role of folate in cellular metabolism," in Folate in Health and Disease, ed. L. B. Bailey (New York: Marcel Dekker), 23-42.
89. Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
90. Wang, Y., Yang, H., Li, L., Wang, H., Zhang, C., Yin, G., et al. (2010). Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur. J. Cancer 46, 758-764.
91. Watzinger, F., and Lion, T. (1999). RAS family. Atlas Genet. Cytogenet. Oncol. Haematol. Available at: http://AtlasGeneticsOncology.org/Deep/Ras.html
92. Whibley, C., Pharoah, P. D. P., and Hollstein, M. (2009). p53 Polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95-107.
93. Winski, S. L., Koutalos, Y., Bentley, D. L., and Ross, D. (2002). Subcellular localization of NAD(P)H: quinone oxidoreductase 1 inhuman cancer cells. Cancer Res. 62, 1420-1424.
94. Woodford-Richens, K. L., Rowan, A. J., Poulsom, R., Bevan, S., Salovaara, R., Aaltonen, L. A., et al. (2001). Comprehensive analysis of SMAD4 mutations and protein expression in juvenile polyposis: evidence for a distinct genetic pathway and polyp morphology in SMAD4 mutation carriers. Am. J. Pathol. 159, 1293-1300.
95. Wrana, J. L. (2000). Regulation of Smad activity. Cell 100, 189-192.
96. Zare, M., Jazii, F. R., Alivand, M. R., Nasseri, N. K., Malekzadeh, R., and Yazdanbod, M. (2009). Qualitative analysis of adenomatous polyposis coli promoter: Hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer 9:24. doi:10.1186/1471-2407-9-24
97. Zauber, A. G., O'Brien, M. J., and Winawer, S. J. (2002). On finding flat adenomas: is the search worth the gain? Gastroenterology 122, 839-840.
98. Zhou, G. W., Hu, J., and Li, Q. (2010). CYP2E1 Pst/Rsa polymorphism and colorectal cancer risk: a meta-analysis. World J. Gastroenterol. 16, 2949-2953.